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PCLINICAL RESEARCH Atherosclerosis
Plasma Interleukin-5 Levels
Are Related to Antibodies Binding
to Oxidized Low-Density Lipoprotein
and to Decreased Subclinical Atherosclerosis
Maritta Sämpi, MS,* Olavi Ukkola, MD, PHD,* Markku Päivänsalo, MD, PHD,‡
Y. Antero Kesäniemi, MD, PHD,* Christoph J. Binder, MD, PHD,§ Sohvi Hörkkö, MD, PHD†
Oulo, Finland; and Vienna, Austria
Objectives This study’s aim was to assess the role of interleukin (IL)-5 in modulating the levels of antibodies binding to oxi-
dized low-density lipoprotein (OxLDL) in human atherosclerosis.
Background Various pro- and anti-inflammatory cytokines have been implicated in atherogenesis, and recent findings in mice
indicate that the cytokine IL-5 plays a protective role in atherosclerosis in part via the induction of antibodies
binding to OxLDL.
Methods Plasma IL-5 levels and antibody titers to 2 most commonly used models of OxLDL (copper OxLDL and
malondialdehyde-modified LDL) were measured in 1,011 Finnish middle-aged subjects with chemiluminescent
enzyme-linked immunosorbent assay. Intima-media thickness (IMT) was assessed ultrasonographically from the
internal carotid artery, the bifurcation, and the common carotid artery.
Results There was a significant positive association between plasma IL-5 levels and antibody titers to copper OxLDL
(p  0.010 and p  0.044, immunoglobin [Ig] M and G, respectively) and IgM to malondialdehyde-modified LDL
(p  0.001) in the association analysis performed between different IL-5 quartiles. Furthermore, plasma IL-5
levels were found to be inversely associated with bifurcational IMT, and even after adjustments for traditional
risk factors of atherosclerosis (age, gender, smoking, systolic blood pressure, LDL, and body mass index), IL-5
remained an independent determinant of the mean bifurcational IMT
(p  0.010).
Conclusions Our data demonstrate that plasma IL-5 levels are related to the plasma levels of antibodies binding to OxLDL
and to decreased subclinical atherosclerosis in humans. These results are in line with earlier findings in murine
atherosclerosis and indicate for the first time that IL-5 may play a role in human atherosclerosis. (J Am Coll
Cardiol 2008;52:1370–8) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.047T
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atherosclerosis is a complex, multifactorial vascular disease
ith both chronic and acute manifestations (1). One im-
ortant factor modulating atherogenesis is the immune
ystem, with both innate and adaptive immunity affecting
he atherosclerotic disease processes in the artery wall (1–3).
rom the *Department of Internal Medicine, Biocenter Oulu, †Department of
harmacology and Toxicology, University of Oulu and Clinical Research Center of
ulu University Hospital, and the ‡Department of Radiology, University of Oulu,
ulu, Finland; and the §Center for Molecular Medicine of the Austrian Academy of
ciences and Department of Medical and Chemical Laboratory Diagnostics, Medical
niversity of Vienna, Vienna, Austria. This work was supported by the Academy of
inland, Finnish Foundation for Cardiovascular Research, Sigrid Juselius Foundation
nd Paulo Foundation. Drs. Binder and Hörkkö contributed equally to this work.
tephen Nicholls, MD, served as Guest Editor for this article.h
Manuscript received April 9, 2008; revised manuscript received June 3, 2008,
ccepted June 3, 2008.here are several candidate pathogens or pathogenic pro-
esses that can elicit localized inflammatory responses and
ubsequent atherosclerotic lesion formation (1–3). Impor-
antly, several pro- and anti-inflammatory cytokines have
een found to regulate this inflammatory process (4,5).
See page 1379
One well-defined set of potential pathogens is generated
y the oxidation of low-density lipoprotein (LDL) leading
o the formation of OxLDL, which is recognized by specific
nnate and adaptive immune responses (6). These responses
nclude the generation of both immunoglobin (Ig) G and M
ntibodies against OxLDL (6), which can be found in
umans and animal models of atherosclerosis. Although the
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October 21, 2008:1370–8 IL-5, OxLDL Antibodies, and Atherosclerosisxact role of these autoantibodies in atherosclerosis is still
lusive, there is accumulating evidence that IgM antibodies
gainst OxLDL in particular seem to inversely correlate
ith surrogate markers of cardiovascular disease, suggesting a
rotective role of this class of antibodies (7–10). In murine
odels of atherosclerosis, IgM antibodies dominate the
umoral response to OxLDL, of which many seem to be
aturally occurring antibodies (6,11,12). These IgM anti-
odies have been shown to recognize their cognate epitopes/
ntigens in atherosclerotic lesions and have been suggested
o actively modulate atherogenic processes by their ability to
lock the uptake of OxLDL and apoptotic cells by macro-
hages through scavenger receptors, thereby limiting the for-
ation of foam cells (11,13–15). In particular, the proto-
ypic natural germline IgM antibody T15/EO6 is expanded
uring atherogenesis in mice (15). T15/EO6 antibodies
ind phosphocholine (PC), which is present in oxidized
hospholipids of OxLDL, as well as the capsular polysac-
haride of Streptococcus pneumoniae (15). We previously
howed that immunization of LDL receptor/
LDLR/) mice with pneumococcal extracts led to a near
onoclonal expansion of T15/EO6 IgM and significantly
ecreased atherosclerotic lesion formation (16). In contrast,
nly very low IgG titers against PC were induced consistent
ith the T-cell independent nature of this response. IgM
ntibodies with similar reactivity seem to exist in humans as
ell, as we found that IgM titers to copper OxLDL
CuOx-LDL) and capsular polysaccharide correlate signif-
cantly in patients with pneumococcal pneumonia (16).
oreover, immunization of atherosclerosis-prone mice or
abbits with model oxidation epitopes, such as
alondialdehyde-modified LDL (MDA-LDL) has been
hown in a number of studies to induce specific antibodies
nd to provide atheroprotection (17–22). In a recent study, we
urther characterized this response and demonstrated that
mmunization of LDLR/ mice with homologous MDA-
DL led to a dominant induction of the Th2 cytokine IL-5
nd to a noncognate expansion of natural T-cell indepen-
ent T15/EO6 antibodies (19). We further showed that
his expansion of T15/EO6 IgM was dependent on the
resence of IL-5, as IL-5 deficient mice did not exhibit this
esponse. Importantly, reconstitution of LDLR/ mice
ith bone marrow from IL-5 deficient donors resulted in
ignificantly more atherosclerosis when compared with re-
ipients of wild-type bone marrow. Thus, IL-5 has an
theroprotective role in vivo and is critically involved in the
roduction of beneficial natural IgM Abs T15/EO6 (19).
his hypothesis was recently strengthened by Miller et al.
23), who demonstrated that induction of IL-5 and anti-
odies to OxLDL with cytokine IL-33 resulted in athero-
rotection in apolipoprotein E/ mice (23). Furthermore,
o-administration of the anti–IL-5 antibody with IL-33
educed the levels of anti-OxLDL antibodies and prevented
he reduction of atherosclerotic plaque size (23).
IL-5 is a pleiotropic cytokine that is known to stimulate
cells and eosinophils (24). In particular, human IL-5 was dhown to enhance the respon-
iveness of certain pathogen-
timulated B-cells and to be an
ssential factor for terminal eo-
inophil differentiation as well as
osinophil activation (24), but its
otential effects in human ath-
rosclerosis are unknown. The
im of the present study was to
nvestigate the potential connec-
ion between IL-5 and antibod-
es binding to OxLDL in a large
andomly selected population-
ased cohort representative of a
iddle-aged Finnish population,
nd to assess how IL-5 levels are
elated to early subclinical ath-
rosclerosis measured by carotid
ntima-media thickness (IMT).
ethods
ubjects. Plasma IL-5 levels, antibodies binding to OxLDL
nd IMT were measured from a study group of 1,011
articipants of the OPERA (Oulu Project Elucidating Risk
f Atherosclerosis) study cohort, which is a population-
ased epidemiological study addressing the risk factors and
isease end points of atherosclerotic cardiovascular diseases.
he study design and the characteristics of the subjects have
een previously described in detail (25–27). Briefly, the
PERA cohort consists of randomly selected subjects from
he Finnish Social Insurance Institute register living in Oulu
egion in Northern Finland. The overall participation rate
as 87.1%, and the initial population consisted of 1,200
ubjects ages 40 to 59 years at the time of recruitment. Of
he total population, 86 subjects had coronary heart disease,
3 subjects were diabetic, 542 subjects used blood pressure-
owering medication, 30 subjects used lipid-lowering med-
cation, 58 subjects used aspirin, 23 subjects used oral
iabetes medication, 13 subjects used insulin, and 112
ubjects were undergoing hormone replacement therapy. A
otal of 189 of the original subjects were excluded from the
resent study due to missing samples or data. Clinical
haracteristics of the study subjects are expressed in Table 1.
n informed consent was obtained from each participant
nd the study was approved by the Ethical Committee of
he Faculty of Medicine, University of Oulu and followed
he principles of the Declaration of Helsinki.
arotid ultrasonography. The carotid ultrasound mea-
urements have been previously described in detail in
äivänsalo et al. (25). Intima-media thickness was measured
y a trained radiologist blinded to the clinical data. A duplex
ltrasound system with 7.5-MHz scanning frequency in
-mode, pulsed Doppler mode, and color mode was used
Toshiba SSA-270A, Toshiba Corp., Tokyo, Japan). IMT,
Abbreviations
and Acronyms
BMI  body mass index
CuOx-LDL  copper
oxidized low-density
lipoprotein
Ig  immunoglobulin
IL  interleukin
IMT  intima-media
thickness
LDL  low-density
lipoprotein
LDLR  low-density
lipoprotein receptor
MDA-LDL 
malondialdehyde-modified
low-density lipoprotein
PC  phosphocholine
OxLDL  oxidized low-
density lipoproteinefined as the distance between the media-adventitia inter-
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IL-5, OxLDL Antibodies, and Atherosclerosis October 21, 2008:1370–8ace and the lumen-intima interface, was measured on the
ollowing 5 points at each side: internal carotid artery,
ifurcation, and common carotid artery (at 3 different
ocations). The intrareader reproducibility of the IMT
easurements was assessed from the videotapes 1.5 years
fter the subject examinations. The IMT measurements
ere done for 31 randomly selected subjects (10 men age
57 years, 11 women age 43 years, and 10 women age
57 years) by 2 radiologists blind to the original results.
he intrareader variability and correlation coefficient for the
ean IMT (common carotid artery/bifurcation/internal
arotid artery) were 3% and 0.97 (Pearson’s coefficient).The
espective interreader variability and correlation values were
.2% and 0.93.
linical measurements. Routine clinical laboratory tests
ere carried out in the Central Laboratory of the Oulu
niversity Hospital. All the laboratory blood test samples
ere obtained after a 12-h request fast. Venous blood was
rawn into ethylenediaminetetraacetic acid tubes. Plasma
as separated by centrifugation at 2,000 rpm for 10 min and
ept at 4°C until further analysis. Plasma total cholesterol
nd triglyceride levels were determined by enzymatic color-
metric methods, and lipoprotein fractions were separated
y ultracentrifugation. The glucose concentrations were mea-
ured using the glucose-oxidase method (Diagnostica, Merck,
hitehouse Station, New Jersey). C-reactive protein was
easured using commercially available enzyme-linked immu-
haracteristics of the Study Subjects
Table 1 Characteristics of the Study Subjects
Variable Mean (SD) Median (IQR)
Count (N) 1,011 —
Male, % (n) 49.1 (496) —
Female, % (n) 50.9 (515) —
Number of current smokers, % (n) 28.5 (288) —
Age (yrs) 51.3 (6.0) 51.3 (46.0–56.5)
BMI (kg/m2) 27.7 (4.6) 26.9 (24.4–30.2)
Waist-to-hip ratio 0.87 (0.09) 0.87 (0.79–0.93)
Plasma lipids (mmol/l)
Total cholesterol 5.69 (1.05) 5.67 (4.97–6.31)
LDL-cholesterol 3.52 (0.94) 3.49 (2.91–4.12)
HDL-cholesterol 1.35 (0.38) 1.29 (1.08–1.57)
Triglycerides 1.57 (1.00) 1.31 (0.97–1.85)
Blood pressure (mm Hg)
Systolic 148 (22) 147 (133–162)
Diastolic 89 (12) 90 (81–97)
Fasting blood glucose (mmol/l) 4.73 (1.47) 4.40 (4.10–4.80)
Plasma IL-5 (pg/ml) 1,511 (9,924) 139 (66–365)
hsCRP (mg/l) 3.75 (7.43) 1.53 (0.71–3.73)
IMTmean (mm)
ICA 0.78 (0.17) 0.75 (0.68–0.85)
BIF 0.94 (0.21) 0.90 (0.78–1.05)
CCA 0.91 (0.19) 0.88 (0.80–0.98)
IF  bifurcation enlargement; BMI  body mass index; CCA  common carotid artery; HDL 
igh-density lipoprotein; hsCRP  highly sensitive C-reactive protein; ICA  internal carotid artery;
L  interleukin; IMT  intima-media thickness; IQR  interquartile range; LDL  low-density
ipoprotein.osorbent assay kit (Diagnostic Systems Laboratories, Web- ster, Texas). Body mass index (BMI) was calculated as weight
kilograms) divided by height (meters) squared.
easurements of plasma IL-5. Plasma IL-5 concentra-
ion was determined in duplicates by a chemiluminescence-
ased enzyme-linked immunosorbent assay using commer-
ially available antibodies and recombinant IL-5 (R&D
ystems, Inc., Minneapolis, Minnesota). The interassay
oefficient of variation for the measurements was 15%.
utoantibody measurements to OxLDL. The levels of
gM, IgG, and IgG2 autoantibodies binding to MDA-LDL
nd CuOx-LDL were determined by chemiluminescence-
ased enzyme-linked immunosorbent assay as described (8).
ntigens, prepared as previously described, were coated at
0 g/ml in phosphate-buffered saline with 0.27 mmol/l
thylenediaminetetraacetic acid and incubated overnight at
°C in white MicroFluor plates (Dynatech Laboratories,
hantilly, Virginia). Plasma samples were diluted 1:1,000
or IgM, 1:500 for total IgG, and 1:50 for IgG2 and
ncubated 1 h at room temperature. Plates for IgM and IgG
ere incubated with an alkaline phosphatase-labeled goat
ntihuman-IgM or -IgG (Sigma-Aldrich, St. Louis, Mis-
ouri) for 1 h at room temperature. Luminescence was
easured 90 min after addition of LumiPhos 530 (Lumi-
en, Southfield, Michigan) using a Victor2 Luminometer
Wallac, Perkin-Elmer, Waltham, Massachusetts). For
gG2 binding, plates were first incubated with biotin-
abeled mouse antihuman-IgG2 (Pharmingen, BD Bio-
cience, San Jose, California), followed by alkaline
hosphatase-labeled NeutrAvidin (Pierce, Thermo-
cientific, Rockford, Illinois) and LumiPhos 530. Triplicate
eterminations were performed for each plasma sample. A
tandard curve of human IgM or IgG and a control plasma
ample was added to each plate to correct potential varia-
ions between the assays, and the data are expressed as
elative units equivalent to control IgM or IgG. The
nterassay coefficients of variation were as follows: IgM,
3.6% for CuOx-LDL and 10.0% for MDA-LDL; IgG,
1.5% for CuOx-LDL and 9.1% for MDA-LDL; and
gG2, 11.9% for CuOx-LDL and 10.3% for MDA-LDL.
tatistical analyses. Statistical analyses were performed
sing the SPSS (version 10.1, SPSS, Inc., Chicago, Illinois)
tatistical package. The association of IL-5 to other vari-
bles determined from the OPERA cohort was studied by
orrelation analysis, 1-way analysis of variance and linear
egression analysis. The correlation between IL-5 and the
ther variables was assessed using partial Pearson correlation
nalysis. After that, the subjects were divided into quartiles
f IL-5 and the means of identified variables were compared
sing 1-way analysis of variance. To control the effect of
onfounding factors on IMT, results were adjusted for the
nown risk factors of atherosclerosis (age, gender, systolic
lood pressure, smoking as pack-years, LDL-cholesterol,
nd BMI) (28) using analysis of covariance. In further
nalysis, the role of IL-5 as a possible independent deter-
inant on IMT was assessed using multiple linear regres-ion analysis. The same risk factors for atherosclerosis as
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October 21, 2008:1370–8 IL-5, OxLDL Antibodies, and Atherosclerosisbove were entered into the regression model together with
L-5. The mean wall value of the IMT of the carotid
ifurcation (indicated as BIFmean) was used as the indepen-
ent variable in all regression analysis. In all analyses,
og-transformed values were used whenever needed to
ormalize the skewed distributions. Statistical significance
as defined as p  0.05.
esults
ntibodies binding to oxidized LDL and IL-5 levels.
ur studies in mice have demonstrated that the induction of
he oxidized phospholipid-specific natural IgM antibody
O6 triggered by immunization with MDA-LDL is de-
endent on the cytokine IL-5. Therefore, we first evaluated
lasma IL-5 levels as well as antibody titers to the 2 most
idely used models of oxidized-LDL (i.e., CuOx-LDL and
DA-LDL). The median for plasma IL-5 concentration
Figure 1 Plasma Antibody Titers to OxLDL by IL-5 Quartiles
Gender-adjusted IgM (A, B), total IgG (C, D), and IgG2 (E, F) antibodies binding to
The data shown is mean (standard error of the mean). CuOx-LDL  copper oxidize
dehyde-modified low-density lipoprotein; OxLDL  oxidized low-density lipoprotein;f the whole study group was 139 (interquartile range: 66 to
65 pg/ml). The mean plasma IL-5 concentration of the
hole study group (n  1,011) was 1,511 (9,924) pg/ml
mean  SD), and it was significantly higher in men (1,740 
1,730 pg/ml, p  0.002) than in women (1,289  7,805
g/ml). For further analyses, the entire study group was
ivided up into quartiles according to the measured plasma
L-5 levels. Figure 1 demonstrates IgM, total IgG, and
gG2 antibody titers to CuOx-LDL and MDA-LDL
ithin the various plasma IL-5 quartiles, after adjusting for
ender. The levels of IgM antibodies binding to both
odels of OxLDL were lowest in the lowest IL-5 quartile
nd highest in the highest IL-5 quartile (p 0.010 and p
.001, CuOx-LDL and MDA-LDL, respectively) (Figs.
A and 1B), demonstrating a clear correlation between
xidation-epitope–specific IgM and IL-5 in the plasma. In
ontrast, only IgG antibodies to CuOx-LDL, but not to
-LDL and MDA-LDL by IL-5 quartiles among the whole study group (N  1,011).
ensity lipoprotein; Ig  immunoglobin; IL  interleukin; MDA-LDL  malondial-
relative units.CuOx
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IL-5, OxLDL Antibodies, and Atherosclerosis October 21, 2008:1370–8DA-LDL showed a similar—albeit less pronounced—
elationship (p  0.044). Moreover, we also assessed
gG2 levels, as this isotype dominates the anti-PC
esponse in humans (29). However, IgG2 titers to CuOx-
DL, which contains PC epitopes, did not show this
trict relationship with IL-5 plasma levels. Because men
ad significantly higher IL-5 levels than women, we
onducted additional analyses separately for men and
omen. The results were analogous: lowest levels of
ntibodies binding to oxidized LDL were observed in the
owest IL-5 quartile and vice versa. Thus, in humans
redominantly IgM antibodies and to a lesser degree IgG
ntibodies to OxLDL are associated with plasma IL-5
evels, indicating a role for this cytokine in the production
f anti-OxLDL antibodies.
Figure 2 Bifurcational Carotid Artery IMT by IL-5 Quartiles
Bifurcational carotid artery IMT by IL-5 quartiles among the whole study group (N 
surements (A, B), far-wall measurements (C, D), and mean IMT (E, F). Adjustmen
tein cholesterol, and body mass index. The data shown is mean (standard error ofL-5 levels and subclinical atherosclerosis. We then as-
essed the possible link between plasma IL-5 concentrations
nd subclinical atherosclerosis measured by IMT. We have
arlier demonstrated in mice that natural antibodies binding
o OxLDL possess atheroprotective properties and confer
theroprotection in vivo (14,16), and that mice deficient in
L-5 have diminished levels of natural IgM to OxLDL and
ccelerated atherosclerosis (19). The connection between
MT and cardiovascular disease in humans has been estab-
ished by others (30). Figure 2 demonstrates the IMT in the
arotid bifurcation according to IL-5 quartiles, before and
fter adjusting for traditional risk factors of atherosclerosis
age, gender, smoking, systolic blood pressure, LDL cho-
esterol, and BMI) among all the study subjects. The mean
arotid artery bifurcational intima media was thinnest in the
1) before and after adjustments. Analyses were performed on the near-wall mea-
e made for age, gender, smoking, systolic blood pressure, low-density lipopro-
ean). IMT  intima-media thickness; other abbreviations as in Figure 1.1,01
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October 21, 2008:1370–8 IL-5, OxLDL Antibodies, and Atherosclerosisighest IL-5 quartile among all the study subjects (p 
.023 and p  0.010, before and after adjustments, respec-
ively) (Figs. 2E and 2F). Also, the bifurcational near-wall
MT (Figs. 2A and 2B) and far-wall IMT measurements
Figs. 2C and 2D) were smallest in the highest IL-5 quartile
Fig. 2). In a multiple linear regression model analysis on
actors affecting the bifurcational IMT, the plasma level of
L-5 was an independent determinant of the mean bifur-
ational carotid artery IMT (BIFmean) in the study popula-
ion (Table 2). In fact, the regression model was able to
xplain 14.0% (R2  0.140, p  0.001) of the total variance
n the mean bifurcational IMT of the study population. In
his model, IL-5 alone could explain 0.6% of the variance of
he mean bifurcational IMT (R2 change for IL-5  0.006,
 0.008). The IMT measurement was also performed in
ther parts of the carotid artery; yet, IL-5 levels were
nversely related only to the IMT of bifurcational section of
he carotid artery, but not to the internal or common carotid
rtery (data not shown). Collectively, these data imply that
here is an epidemiological link between plasma IL-5 levels
nd atherosclerosis in humans and suggest that IL-5 is also
n atheroprotective cytokine in humans.
The variation of several other known risk factors of
therosclerosis and the bifurcational IMTs between IL-5
uartiles is presented in Table 3. High-density lipoprotein
holesterol levels were inversely related to IL-5 levels (p 
.001), and therefore the association analyses were addition-
lly adjusted for high-density lipoprotein cholesterol. When
he analyses were repeated after adjusting for age, gender,
moking, systolic blood pressure, and high-density lipopro-
ein cholesterol, the bifurcational IMT remained the only
tatistically significant carotid artery location in different
L-5 quartiles (p  0.013, 0.035, and 0.008 for near-wall,
ar-wall, and mean IMT, respectively).
iscussion
here is clear evidence that both the adaptive and innate
mmune system are involved in the natural course of
therogenesis (2,3), and our recent study (19) in mice
emonstrated an atheroprotective role for the Th2 cytokine
L-5 in part through the induction of natural antibodies
gainst oxidized phospholipids. Cytokines have been impli-
ated as major players in the atherosclerotic disease process
inear Regression Analysis Model of Factors Affecting the IMTmean
Table 2 Linear Regression Analysis Model of Factors Affecting
Variable R2
Change Statistics
R2 Change p
Age 0.065 0.065 <
Gender 0.108 0.043 <
LDL-cholesterol 0.118 0.010
IL-5 0.124 0.006
BMI 0.131 0.007
Systolic BP 0.140 0.009
2odel R  0.140; p  0.001. Bold p values are statistically significant.
BP  blood pressure; SEM  standard error of the mean; other abbreviations as in Table 1.n many ways (5). The purpose of the present study was to
valuate in humans the possible involvement of the candi-
ate cytokine IL-5 in modulating the levels of antibodies
inding to OxLDL and its role in human atherosclerosis.
e here show that plasma IL-5 levels are related to the
evels of antibodies binding to OxLDL in a large randomly
elected population-based cohort representative of middle-
ged Finnish population. Importantly, we also found that
L-5 levels are inversely related to early subclinical athero-
clerosis as measured by bifurcational carotid artery IMT.
IL-5 is expressed in human carotid atherosclerotic
laques (31) and in abdominal aortic aneurysms (32),
hough irregularly and at low levels. Until now, only small
mounts of data were available on the relationship of plasma
L-5 with human atherosclerosis. In a recent study, Inoue
t al. (33) evaluated the predictive value of plasma cytokine
evels, including IL-5, on cardiovascular events in 158
atients. In their study, IL-5 levels predicted cardiovascular
vents, though only in an univariate analysis (33). In another
tudy by Avramakis et al. (34), only patients with myocar-
ial infarction and unstable angina had detectable levels of
L-5, whereas IL-5 was not detected in the plasma of
ealthy controls. Thus, in these studies, plasma IL-5 levels
eemed to be increased in patients at risk of clinical vascular
vents (33,34). It is noteworthy that the mean plasma IL-5
evels reported in both studies mentioned were significantly
ower (20 pg/ml) than what we measured in our healthy
nd much larger population (mean 1,511 pg/ml). Because
ethodological origins for the low IL-5 levels in these
tudies are not clearly evident, this could imply that patients
ith advanced cardiovascular disease may already have
uch lower plasma IL-5 levels than the healthy population
oes. In analogy to our data, the median serum IL-5 levels
f healthy mothers and their 1-year-old babies were re-
orted to be above 120 pg/ml (35). In light of this, the lower
lasma IL-5 levels found in patients with cardiovascular
isease (33,34) further support a protective role of IL-5.
urthermore, we found that high plasma IL-5 levels were
ssociated with smaller bifurcational carotid artery IMT,
nd that this was statistically significant after adjusting for
ther well-established risk factors, such as age, gender,
moking, systolic blood pressure, LDL-cholesterol, and
MI. Interestingly, our finding on the association between
IFmean of the Study Population (N  1,011)
MTmean of BIFmean of the Study Population (N  1,011)
B (SEM) Beta p Value
0.004 (0.000) 0.244 0.001
0.034 (0.005) 0.189 0.001
0.011 (0.003) 0.112 0.001
0.011 (0.004) 0.080 0.007
0.142 (0.040) 0.111 0.001
0.000 (0.000) 0.100 0.002of B
the I
Value
0.001
0.001
0.001
0.008
0.005
0.002
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IL-5, OxLDL Antibodies, and Atherosclerosis October 21, 2008:1370–8L-5 levels and IMT was significant only in measurements
erformed at the bifurcation of the carotid artery, but not in
easurements performed in other parts of the carotid. This
uggests that the atheroprotective role of IL-5 is particularly
rominent at sites of disturbed flow that are especially
usceptible to lesion formation. Thus, an IL-5–dependent
rotective mechanism may be specifically important at these
ites.
IL-5 has a central role in B-cell biology (24,36,37). It is
articularly important in the homeostatic proliferation,
urvival, and Ig production of murine B-1 cells (38), which
onstitutively express the IL-5R and are the major source of
atural IgM antibodies (39), including T15/EO6 (15,16).
L-5 transgenic mice have higher levels of serum IgM and
gA, as well as increased numbers of B-1 cells (40). In
ontrast, B-cells from IL-5Rec–deficient mice have defec-
ive thymus independent type 2 IgM antibody responses,
uch as those directed against PC (41). The role of IL-5 in
uman B-cell biology is less well established. Here we show
hat IL-5 plasma levels are associated with IgM and to lesser
egree IgG antibodies to epitopes of OxLDL, thereby
ndicating an in vivo function of IL-5 in stimulating specific
uman (IgM) antibody responses. These findings are anal-
gous to our previous data in LDLR/ mice, in which
L-5 stimulated the production of B-1 cell-derived IgM
bs of the T15 idiotype, but not IgG antibodies (19).
mportantly, recent epidemiological studies suggest a dif-
erential effect of IgM versus IgG antibodies against OxLDL
9). The IgM autoantibodies to OxLDL have been docu-
ented to be inversely related to measures of human
therosclerosis (8,9), suggesting a possible protective role,
hereas IgG to OxLDL did not show such a relationship
9). Thus, IL-5 may mediate its protective effect by prefer-
haracteristics of the Study Subjects According to the IL-5 Quartil
Table 3 Characteristics of the Study Subjects According to the
1st 38 (24–50) 2nd 95 (80-1
n 256 249
Male/female, % (n) 10.5 (106)/14.8 (150) 11.3 (114)/13.4
Age (yrs) 51 (51–52) 51 (50–52)
BMI (kg/m2) 27.7 (27.2–28.3) 28.1 (27.5–2
Smoking (pack-yrs) 14.2 (12.6–15.8) 13.3 (11.7–1
Systolic BP (mm Hg) 150 (147–152) 149 (147–15
hsCRP (mg/l) 1.60 (0.73–4.53) 1.51 (0.68–4
Diabetes, % (n) 2.2 (22) 1.2 (12)
Total cholesterol (mmol/l) 5.80 (5.67–5.92) 5.67 (5.54–5
LDL-cholesterol (mmol/l) 3.53 (3.42–3.64) 3.49 (3.38–3
HDL-cholesterol (mmol/l) 1.42 (1.38–1.46) 1.33 (1.29–1
Triglycerides (mmol/l) 1.63 (1.51–1.75) 1.64 (1.51–1
IMT BIF near wall (mm) 0.94 (0.92–0.97) 0.93 (0.91–0
IMT BIF far wall (mm) 0.95 (0.92–0.97) 0.96 (0.93–0
IMT BIF mean (mm) 0.94 (0.92–0.97) 0.94 (0.92–0
ata are mean (95% CI), except male/female is % (n) and IL-5 and hsCRP are median (IQR). Statist
The p value is calculated from log-transformed sample values. ‡Adjusted for age and gender. §A
Abbreviations as in Tables 1 and 2.ntially promoting anti-OxLDL IgM responses. In addi- aion, the significant associations between IL-5 and various
sotypes of antibodies binding to OxLDL presented in the
urrent paper seem to favor the PC epitope dominant in
uOx-LDL over the malondialdehyde epitope in MDA-
DL (Fig. 1). This is also consistent with our earlier
ndings in mice, in which we showed that IL-5 promotes
he production of natural EO6 IgM antibodies that specif-
cally recognize PC. As discussed before, PC is a dominant
tructure in Streptococcus pneumoniae as well as in OxLDL
nd gives rise to atheroprotective IgM (EO6) and IgA
T15) subtypes of antibodies in mice. In humans, however,
he nature, role, and subtype of anti–PC-specific antibodies
n atherosclerosis has not been established, although IgM
ut not IgG titers to CuOx-LDL (which contains PC
pitopes) were found to be inversely correlated with coro-
ary stenosis (9). Altogether, our findings demonstrate for
he first time a link between plasma IL-5 levels and specific
IgM) antibodies to neoself epitopes, thereby documenting
uch a functional role of IL-5 in humans.
tudy limitations. In the present study, we have searched
or associations and did not examine the possible underlying
echanisms linking IL-5, antibodies to oxidation epitopes,
nd IMT in humans. It is possible that instead of having an
ctive role in the atherosclerotic disease, such as through
nduction of protective antibodies, IL-5 is merely another
arker. Nevertheless, our earlier studies in IL-5–deficient
DLR/ mice demonstrate a functional role for IL-5 in
therogenesis in mice. In this respect, we find it central to
ur findings that the IL-5 levels of our study subjects were
trongly related to IgM antibody titers to OxLDL, which
ave been clearly demonstrated to have atheroprotective
roperties in mice (14,16) and have been inversely associ-
ted with human atherosclerosis (7–10). We believe that
 1,011)
Quartiles (N  1,011)
uartiles (pg/ml)
p Value3rd 206 (170–275) 4th 809 (511–1,605)
253 253 0.500
) 12.8 (129)/12.3 (124) 14.5 (147)/10.5 (106) 0.001
51 (51–52) 51 (50–52) 0.810*
27.7 (27.1–28.3) 27.2 (26.6–27.8) 0.211*†
13.0 (11.4–14.6) 10.6 (9.0–12.3) 0.037*†
147 (145–150) 147 (144–149) 0.326‡
1.54 (0.76–3.38) 1.53 (0.66–3.26) 0.322†‡
1.0 (10) 1.2 (12) 0.096
5.76 (5.64–5.89) 5.54 (5.41–5.67) 0.023‡
3.65 (3.53–3.76) 3.43 (3.31–3.54) 0.052‡
1.33 (1.29–1.38) 1.32 (1.27–1.36) 0.009†‡
1.53 (1.41–1.65) 1.49 (1.37–1.61) 0.370†‡
0.96 (0.93–0.98) 0.90 (0.87–0.93) 0.021†§
0.95 (0.93–0.98) 0.91 (0.88–0.93) 0.033†§
0.95 (0.93–0.98) 0.90 (0.88–0.93) 0.010†§
nificance was defined as p 0.05. Bold p values are statistically significant. *Adjusted for gender.
d for age, gender, smoking, systolic BP, LDL, cholesterol, and BMI.es (N
IL-5
IL-5 Q
15)
(135
8.7)
5.0)
2)
.26)
.80)
.61)
.38)
.76)
.96)
.98)
.97)
ical sigmong these antibodies in humans there are those resem-
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October 21, 2008:1370–8 IL-5, OxLDL Antibodies, and Atherosclerosisling murine T15/EO6 type of natural antibodies that
xhibit atheroprotective properties (16). Although we can-
ot rule out the possibility that IL-5 also mediates athero-
rotective effects via other mechanisms, such as the promo-
ion of cytotoxic T-cell responses (42) or via natural killer
-cell–mediated immune regulation (43), our findings
trongly suggest a link between IL-5 production and anti-
ody induction to oxidation epitopes in humans that is
imilar to that observed in mice. This link may provide
urther mechanistic insight into earlier studies showing a
rotective role of IgM antibodies to OxLDL in humans
8,10).
onclusions
ur findings demonstrate that human plasma IL-5 levels
re related to antibodies binding to OxLDL and to de-
reased subclinical atherosclerosis. These results are in line
ith the earlier findings in mice and support the concept of
L-5–activated induction of antibodies to oxidation epitopes
nd a protective role of IL-5 in atherosclerosis. Because
trategies are currently being developed to inhibit IL-5
ctions in patients with asthma and other allergic diseases
44), it is important to gain a detailed understanding of the
ole of IL-5 in human atherogenesis.
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